Results 91 to 100 of about 15,932 (195)

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant‐Level Exploratory Analysis of the Randomised CONFIDENCE Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − < 5000 mg/g, estimated glomerular ...
Janet B. McGill, Jennifer B. Green, Hiddo J. L. Heerspink, Johannes F. E. Mann, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Masaomi Nangaku, Meike Brinker, Charlie Scott, Katja Rohwedder, Li Li, Na Li, Margarida Seco, Rajiv Agarwal   +15 more
wiley   +1 more source

The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats

Archives of Epilepsy
Objective: Epilepsy is the most common chronic brain disease that affects millions of people worldwide. In the present study, we investigated the effects of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been recently ...
Hatice Aygün
doaj   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You   +5 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib

BMC Medicine
Background Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity.
Shi-yu Huang, Min Hu, Yu-jie Chen, Jia-chen Liu, Zhi-yuan Yao, Zhi-yuan Chen, Xiu-heng Liu, Lei Wang   +7 more
doaj   +1 more source

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study

Frontiers in Pharmacology
ObjectivesThis study compared the ischemic cardiovascular events (iCVEs) effectiveness and safety of initiating empagliflozin or dapagliflozin with those of dipeptidyl peptidase-4 inhibitors (DPP-4is), as well as the comparative effects between ...
Hayeon Kim, Jun-Ho Seo, Jin Hyun Nam, Yejee Lim, Kyung Hee Choi, Kyungim Kim, Kyungim Kim   +6 more
doaj   +1 more source